Genzyme Campath MS Launch Could Be Delayed Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies of the CLL therapy in multiple sclerosis are targeted to begin in the second half, Genzyme tells “The Pink Sheet” DAILY.